Lev is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. Lev's lead product candidate, Cinryze(TM) (C1 inhibitor), is being developed as a replacement therapy for both the acute and prophylactic treatment of hereditary angioedema (HAE), also known as C1 inhibitor deficiency. Cinryze(TM) has been granted orphan drug status for the acute and prophylactic treatment of HAE, potentially securing, upon approval, market exclusivity for seven years. Additionally, Lev is in the process of prioritizing its C1 inhibitor development platform for the treatment of selective other diseases and disorders in which inflammation is known or believed to play an underlying role.
View Top Employees from Lev Pharmaceuticals| Website | http://www.yelp.com/biz/lev-pharmaceuticals-new-york |
| Revenue | $6.3 million |
| Employees | 2 (2 on RocketReach) |
| Address | 122 W 42nd St Ste 2606, New York City, New York 10168, US |
| Phone | (212) 682-3096 |
| Industry | Financial Services, Manufacturing General, Manufacturing |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 325412 Companies, NAICS Code 325 Companies |
Looking for a particular Lev Pharmaceuticals employee's phone or email?
Lev Pharmaceuticals Questions
The Lev Pharmaceuticals annual revenue was $6.3 million in 2024.
2 people are employed at Lev Pharmaceuticals.
Lev Pharmaceuticals is based in New York City, New York.
The NAICS codes for Lev Pharmaceuticals are [32541, 32, 3254, 325412, 325].
The SIC codes for Lev Pharmaceuticals are [283, 28].
Top Lev Pharmaceuticals Employees
Related Companies
